Rituximab

ATC CODE

  • L01XC02

INDICATIONS AND NEMLC RECOMMENDATIONS

INDICATIONS AND NEMLC RECOMMENDATIONS 1

INDICATION

CD20 positive B-cell non-Hodgkin’s lymphoma: first-line

NEMLC RECOMMENDATION

  • Approved for treatment in diffuse large B-cell non-Hodgkin’s lymphoma (DLBCL) patients except those with International Prognostic Index (IPI) of 0.

REVIEW INDICATORS

  • New anti-CD20 monoclonal antibodies, more data and international consensus statements in FL patients, rituximab price changes

DATE RATIFIED

  • 23 August 2012

INDICATIONS AND NEMLC RECOMMENDATIONS 2

INDICATION

  • Rheumatoid Arthritis patients refractory to synthetic DMARDs.

NEMLC RECOMMENDATION

  • Approved
    • For patients with refractory RA, who have failed ≥ 3 DMARDs taken for ≥ 6 months. (in accordance with algorithm)

REVIEW INDICATORS

  • Evidence of harm

DATE RATIFIED

  • 5 July 2018

INDICATIONS AND NEMLC RECOMMENDATIONS 3

INDICATION

  • Refractory lupus nephritis.

NEMLC RECOMMENDATION

  • Approved- Special Access
    • Special Access may be granted on recommendation by the PTC.
    • Used as per NEMLC-approved treatment algorithm.
      Use must be monitored and managed by PTCs through a registry. Clinical outcomes to be shared with the National registry database for biological therapy.

REVIEW INDICATORS

  • Changes in evidence of efficacy/safety
  • Change in cost

DATE RATIFIED

  • 11 April 2019